Reuters logo
in a month
BRIEF-Karyopharm says top-line data from SADAL study expected in second half of 2018
June 23, 2017 / 10:43 AM / in a month

BRIEF-Karyopharm says top-line data from SADAL study expected in second half of 2018

1 Min Read

June 23 (Reuters) - Karyopharm Therapeutics Inc:

* Karyopharm reports updated Phase 2b SADAL data for Selinexor in diffuse large B-cell lymphoma at the 2017 European Hematology Association Annual Meeting

* Karyopharm Therapeutics Inc says with additional responders, median duration of response remains greater than 7 months

* Karyopharm Therapeutics Inc - top-line data from SADAL study expected in second half of 2018

* Karyopharm Therapeutics Inc - updated Phase 2b SADAL data in relapsed or refractory DLBCL

* Karyopharm Therapeutics Inc - ‍observed responses continue to be durable, with a median DOR of greater than 7 months, including prolonged complete responses​

* Karyopharm Therapeutics Inc - 60mg dose continues to be well tolerated with a low incidence of grade 3 or greater adverse events

* Karyopharm Therapeutics Inc - 60mg treatment arm is enrolling on track, and look forward to reporting top-line data from SADAL study in second half of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below